SN7
SHORT NOTE
5M
Describe the hazards of blood transfusion.
Definition
Blood transfusion is the intravenous administration of whole blood or its components, and its hazards are divided into immunological, infective and other.
Immunological Hazards
| Reaction | Mechanism | Features and management |
|---|---|---|
| Acute haemolytic reaction | ABO incompatibility — preformed IgM; type II hypersensitivity; almost always a clerical error | Fever, loin pain, hypotension, haemoglobinuria, DIC, renal failure. Stop the transfusion immediately, maintain the airway and circulation, and return the unit |
| Delayed haemolytic reaction | Anamnestic response to a minor antigen (Rh, Kidd) 5–10 days later | Falling haemoglobin, jaundice, positive direct Coombs test |
| Febrile non-haemolytic reaction | Antibodies to donor leucocytes; the commonest reaction | Fever and rigors; prevented by leucodepletion |
| Allergic / anaphylactic | Antibodies to plasma proteins; anaphylaxis in IgA-deficient recipients | Urticaria to full anaphylaxis; washed cells for IgA deficiency |
| TRALI (transfusion-related acute lung injury) | Donor anti-leucocyte antibodies activating recipient neutrophils in the lung | Acute dyspnoea and pulmonary oedema within 6 hours, with a normal jugular venous pressure |
| TACO (transfusion-associated circulatory overload) | Volume overload | Dyspnoea with a raised jugular venous pressure; responds to diuretics |
| Transfusion-associated GVHD | Viable donor lymphocytes in an immunosuppressed recipient | Rash, diarrhoea, jaundice and marrow aplasia; mortality over 90%; prevented by irradiating the product |
| Post-transfusion purpura | Anti-HPA-1a antibodies | Severe thrombocytopenia about a week later |
CLINICAL PEARL
TRALI and TACO both cause breathlessness during transfusion, and the jugular venous pressure separates them. TACO is overload, so the JVP is raised and diuretics help. TRALI is capillary leak, so the JVP is normal and diuretics are harmful. Getting this wrong at the bedside does real damage.
Infective Hazards
- Viral — HIV, hepatitis B and C (the chief concerns, now much reduced by screening and nucleic acid testing, but not eliminated because of the window period); cytomegalovirus; HTLV; parvovirus B19
- Bacterial — contamination, particularly of platelets, which are stored at room temperature; causes fulminant septic shock
- Parasitic — malaria, an important risk in India; also babesiosis, Chagas disease, kala-azar
- Syphilis — rare, since the organism does not survive refrigeration
Other Hazards
- Massive transfusion (replacement of one blood volume in 24 hours) — coagulopathy from dilution, hypothermia, citrate toxicity with hypocalcaemia, hyperkalaemia, and acid–base disturbance
- Iron overload in the chronically transfused — thalassaemia, myelodysplasia; each unit contains about 200 mg of iron
- Alloimmunisation, making future cross-matching progressively harder
- Immunomodulation, with a possible increase in postoperative infection
Applied Aspects
- The commonest serious hazard is a clerical error, not an exotic reaction — checking the patient’s identity against the unit at the bedside is the single most important safety step
- Transfuse components, not whole blood, and transfuse for a clinical indication rather than a threshold figure
- Irradiated products for severely immunosuppressed patients, after purine analogues, for intrauterine and neonatal exchange transfusion, and for directed donations from relatives
- Voluntary non-remunerated donation is the safest source; paid and replacement donation carries a higher infection risk, which is why India has moved against it
- Haemovigilance — every reaction should be reported, since systematic reporting is how transfusion safety has improved
- Consent and documentation are required, and the indication should be recorded in the notes
All questions in Haematology II: Leukaemias, Lymphomas & Haemostasis
- Q1Classify leukaemias. Describe the clinical features and laboratory diagnosis of acute leukaemia and differentiate AML from ALL. ★
- Q2Describe chronic myeloid leukaemia and chronic lymphocytic leukaemia with their clinical features and laboratory findings. ★
- Q3Classify lymphomas. Describe Hodgkin lymphoma and differentiate it from non-Hodgkin lymphoma. ★
- Q4Describe the clinical features, laboratory diagnosis and complications of multiple myeloma. ★
- Q5Describe the approach to a patient with a bleeding disorder. Interpret the coagulation screening tests and classify the causes of thrombocytopenia. ★
- SN1Describe immune thrombocytopenic purpura with its types, features and management. ★
- SN2Describe haemophilia with its genetics, clinical features and laboratory diagnosis. ★
- SN3Describe von Willebrand disease and differentiate it from haemophilia A. ★
- SN4Describe the Reed-Sternberg cell with its variants and immunophenotype. ★
- SN5Define leukaemoid reaction. Differentiate it from chronic myeloid leukaemia and add a note on the leucoerythroblastic reaction. ★
- SN6Describe the indications, sites and interpretation of bone marrow examination. ★
- SN7Describe the hazards of blood transfusion.